Menu Search
Equities

ICU Medical Inc

IC7:DUS

ICU Medical Inc

Actions
  • Price (EUR)161.00
  • Today's Change1.00 / 0.63%
  • Shares traded--
  • 1 Year change+111.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ICU Medical Inc had revenues remain flat at 2.28bn, though the company grew net income from a loss of 74.29m to a smaller loss of 29.66m. A reduction in the cost of goods sold as a percentage of sales from 69.40% to 67.25% was a component in the net income growth despite flat revenues.
Gross margin32.87%
Net profit margin-4.74%
Operating margin-0.30%
Return on assets-2.56%
Return on equity-5.35%
Return on investment-2.90%
More ▼

Cash flow in USDView more

In 2023, ICU Medical Inc increased its cash reserves by 21.76%, or 45.44m. The company earned 166.20m from its operations for a Cash Flow Margin of 7.36%. In addition the company used 87.95m on investing activities and also paid 35.98m in financing cash flows.
Cash flow per share4.69
Price/Cash flow per share36.20
Book value per share83.76
Tangible book value per share-8.81
More ▼

Balance sheet in USDView more

ICU Medical Inc has a Debt to Total Capital ratio of 43.82%, a lower figure than the previous year's 75.83%.
Current ratio2.29
Quick ratio1.03
Total debt/total equity0.7799
Total debt/total capital0.4382
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-289.73
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.